Is early anticoagulation necessary after biological aortic valve replacement?

Area of Science:

• Cardiology
• Cardiac Surgery
• Thrombosis Research

Background:

• The optimal antithrombotic strategy following biological aortic valve replacement (AVR) remains unclear.
• Early anticoagulation post-AVR is a subject of ongoing clinical debate.
• Understanding the risk of thromboembolic events (TE) without anticoagulation is crucial for patient management.

Purpose of the Study:

• To evaluate the incidence of thromboembolic events (TE) in patients undergoing biological AVR who did not receive anticoagulation therapy.
• To assess the safety of withholding antithrombotic treatment in the initial 3 months after biological AVR.
• To provide data guiding clinical decisions on antithrombotic management post-biological AVR.

Main Methods:

• Retrospective analysis of 143 consecutive patients who underwent biological AVR between January 1998 and December 2004.
• Inclusion of 127 patients (89%) who did not receive any anticoagulation treatment in the first 3 months post-surgery.
• Monitoring for thromboembolic events, major bleeding, and mortality during the specified period.

Main Results:

• A low rate of thromboembolic events was observed, with 2 strokes (1.5%) occurring within the first 3 months.
• Two major bleeding events (1.5%) were recorded during the same period.
• Nine deaths (7%) occurred, none of which were attributed to thromboembolic complications.

Conclusions:

• Management of patients without antithrombotic treatment after biological AVR appears safe.
• The low incidence of TE suggests that anticoagulation may not be necessary for all patients in the early post-operative period.
• Further research could refine patient selection for non-anticoagulated management post-biological AVR.